Ann: Cyclopharm completes oversubscribed Share Purchase Plan, page-8

Hi all. Interested non-holder here. Looks a very interesting technology and has clearly had a lot of success in countries such as Canada. A question for those that know the company well: is it surprising that total revenues are only at the $26m dollar mark, considering it is an established nuclear medicine technology, apparently best of breed and in so many countries? Is it just the TAM for the indication is not that high or is it still slowly growing market share in those countries? Still reasonable revenue, but for a very good medical product in 60+ countries, I would probably have expected more.